News
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells San Diego, CA – August 19, 2020 – Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast
Read MoreARVO 2020: Proliferation of Human Corneal Endothelia in Organ Culture
Trefoil Therapeutics presents the proliferation of human corneal endothelia in organ culture stimulated by engineered human fibroblast growth factor 1 (FGF1) derivative TTHX1114
Read MoreTrefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Experienced clinical development executive to lead the TTHX1114 clinical study in corneal endothelial disease.
Read MoreTrefoil Therapeutics Selects AGB Biologics tp Supply Lead Compound TTHX1114
AGC selected based on their proven cGMP capabilities as a manufacturer of protein based therapeutics.
Read MoreLead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020.
Read MoreTrefoil Therapeutics Elects Benjamin F. McGraw, III, to its Board of Directors
As the company’s eFGF-1 platform moves forward, Dr. McGraw brings significant high-level experience in development and commercialization.
Read MoreTrefoil Therapeutics Raises $5.2 Million Series 1 Financing
Hatteras Venture Partners leads round which provides funding to reach IND filing for novel corneal endothelial dystrophy therapy.
Read MoreTRND Award Will Accelerate the Development of a New Therapy for Fuchs Dystrophy
Read MoreExpands Research from Endothelial to Epithelial Cell Regeneration
Read MoreEngineered FGF-1 Derivatives Stimulate Proliferation of Corneal Endothelial Cells
Read More